Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck

ANZ Journal of Surgery

Volumn 79, Issue 1-2, 2009, Pages 48-54

  Farhadieh, Ross D ^a,b,c   Smee, Robert ^c,d   Rees, Charles G G ^d   Salardini, Arash ^h   Eggleton, Sarah ^g   Yang, Jia Lin ^e   Russell, Pamela J ^f  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Prince of Wales Oncology Center   (Australia)

^f Prince of Wales Oncology Research Center   (Australia)

^g GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h YALE UNIVERSITY   (United States)

Author keywords

Cyclin A1; Head and neck squamous cell carcinoma; Mut p53; Second primary tumour; Survival

Indexed keywords

BIOLOGICAL MARKER; CYCLIN A1; MUTANT PROTEIN; PROTEIN P53;

ADULT; AGED; CANCER RECURRENCE; CONFERENCE PAPER; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREDICTION; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; SECOND CANCER; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CYCLIN A; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59149088155     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2008.04799.x     Document Type: Conference Paper

References (26)

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 2002 97 : 72 81.
2. de Vries N, van der Waal I, Snow GB. Multiple primary tumours in oral cancer. Int. J. Oral Maxillofac. Surg. 1986 15 : 85 7.
3. Mashberg A. Diagnosis of early oral and oropharyngeal squamous carcinoma: obstacles and their amelioration. Oral Oncol. 2000 36 : 253 5.
4. Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 1990 323 : 795 801.
5. Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann. Otol. Rhinol. Laryngol. 1995 104 : 946 54.
6. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium. Cancer 1953 6 : 963 8.
7. Califano J, van der Riet P, Westra W et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996 56 : 2488 92.
8. Braakhuis BJM, Brakenhoff RH, Leemans CR. Head and neck cancer: molecular carcinogenesis. Ann. Oncol. 2005 16 : 249 50.
9. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordan J. p53: twenty five years understanding the mechanism of genome protection. J. Physiol. Biochem. 2004 60 : 287 307.
10. Tabor MP, Brakenhoff RH, van Houten VM et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin. Cancer Res. 2001 7 : 1523 32.
11. Knudson AG. Cancer genetics. Am. J. Med. Genet. 2002 111 : 96 102.
12. Chung KY, Mukhopadhyay T, Kim J, Casson A. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res. 1993 53 : 1676 83.
13. van Oijen MG, Leppers Vd Straat FG, Tilanus MG et al. The origins of multiple squamous cell carcinomas in the aerodigestive tract. Cancer 2000 88 : 884 93.
14. Ribeiro U, Safatle-Ribeiro AV, Posner MC et al. Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. Surgery 1996 120 : 45 53.
15. Sweeney C, Murphy M, Kubelka M et al. A distinct cyclin A is expressed in germ cells in the mouse. Development 1996 122 : 53 64.
16. Diederichs S, Bäumer N, Ji P et al. Identification of interaction partners and substrates of the cyclin A1-CDK2 complex. J. Biol. Chem. 2004 279 : 33727 41.
17. Yang R, Nakamaki T, Lübbert M et al. Cyclin A1 expression in leukemia and normal hematopoietic cells. Blood 1999 93 : 2067 74.
18. Yang R, Morosetti R, Koeffler HP. Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res. 1997 57 : 913 20.
19. Tokumaru Y, Yamashita K, Osada M et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004 64 : 5982 7.
20. Leemans CR, Tiwari R, Nauta JJ et al. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 1993 71 : 452 6.
21. Yang R, Müller C, Huynh V et al. Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins. Mol. Cell. Biol. 1999 19 : 2400 407.
22. Nakamaki T, Hamano Y, Hisatake J et al. Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival. Br. J. Haematol. 2003 123 : 72 80.
23. Wegiel B, Bjartell A, Ekberg J et al. A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. Oncogene 2005 24 : 6385 93.
24. Müller-Tidow C, Diederichs S, Schrader MG et al. Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. Cancer Lett. 2003 190 : 89 95.
25. Braakhuis BJM, Tabor MP, Leemans CR et al. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 2002 24 : 198 206.
26. Warren S, Gates O. Multiple primary malignant tumours. A survey of the literature and a statistical study. Am. J. Cancer 1932 16 : 1358 414.